The report provides a detailed analysis essential for establishing a sarecycline hydrochloride production plant. It encompasses all critical aspects necessary for sarecycline hydrochloride production, including the cost of sarecycline hydrochloride production, sarecycline hydrochloride plant cost, sarecycline hydrochloride production costs, and the overall sarecycline hydrochloride production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a sarecycline hydrochloride production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.
Sarecycline hydrochloride is a tetracycline antibiotic that is used for treating inflammatory lesions of non-nodular moderate to severe acne vulgaris. It is utilised in patients aged 9 years and older, offering targeted antibacterial action against Cutibacterium acnes. It is administered once daily at a weight-based dose, and has demonstrated approximately 52% reduction in acne lesions over 12 weeks in clinical trials. It also provides anti-inflammatory effects without common tetracycline side effects like photosensitivity or dizziness. It is approved by the FDA as a convenient oral option for facial, chest, and back acne, particularly in adolescents. Its common side effects include nausea, headache, nasopharyngitis (common cold symptoms), vomiting, and vaginal yeast infections.
The market for sarecycline hydrochloride is driven by the high global cases of acne vulgaris. The rising antimicrobial resistance in Cutibacterium acnes strains, limiting older tetracyclines like doxycycline, contributes to its demand. Its effectiveness for targeting acne-causing bacteria with fewer side effects, such as photosensitivity or GI upset, boosts its market. The industrial sarecycline hydrochloride procurement is influenced by patented status, delaying generics, along with a few API suppliers requiring specialised synthesis. The premium pricing and payer prior authorisations favouring branded over potential generics, unreliable cold-chain logistics and import reliance, and competition from topical alternatives or minocycline biosimilars impact its market dynamics.
Raw Material for Sarecycline Hydrochloride Production
According to the sarecycline hydrochloride production plant project report, the key raw materials used in the production of sarecycline hydrochloride include sancycline, N-iodosuccinimide, and trifluoroacetic acid.
Production Process of Sarecycline Hydrochloride
The extensive sarecycline hydrochloride production cost report consists of the following major industrial production process:
- From sancycline: The production process of sarecycline hydrochloride involves several steps. First, iodination with N-iodosuccinimide in trifluoroacetic acid takes place to give iodosancycline trifluoroacetate. This intermediate undergoes palladium-catalysed carbonylation in N-methylpyrrolidone (NMP) to form 7-formylsancycline trifluoroacetate, followed by reductive amination with N,O-dimethylhydroxylamine using oxalic acid, dimethylamine borane, and sodium cyanoborohydride. This is followed by HCl salting and precipitation to give sarecycline hydrochloride as the final product.
Sarecycline hydrochloride has the molecular formula of C24H30ClN3O8 and a molecular weight of 523.97 g/mol. It appears as a white to off-white crystalline powder with defined stereochemistry. This includes a dimethylamino group at position 4, a methoxy(methyl)aminomethyl substituent at position 7, multiple hydroxy groups, and a carboxamide on the linear tetracene core. It shows good oral bioavailability due to optimised lipophilicity and pH-dependent aqueous solubility suitable for tablet formulation. It shows chemical stability under physiological conditions, enabling once-daily dosing, and selective activity against Cutibacterium acnes with minimal gut microbiome disruption compared to broader tetracyclines.